Jian Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jian Liu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Baiyou Tang
Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China
1 shared publication- Can Chen
University of North Carolina at Chapel Hill
1 shared publication - Chengmin Zhang
Department of Orthopedics Southwest Hospital, Third Military Medical University (Army Medical University) Chongqing People's Republic of China
1 shared publication - Fei Luo
Department of Orthopedics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China
1 shared publication - Fengqiao Li
Fuzhou University
1 shared publication - Hao Mei
Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60603, USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2021
- Published by KEAI Publishing in Bioactive Materials
- Vol. 6 (10) , 3192-3193
Corrigendum to ’Phosphorylation inhibition of protein-tyrosine phosphatase 1B tyrosine-152 induces bone regeneration coupled with angiogenesis for bone tissue engineering’ [Bioactive Mater. Vol. 6, Issue 7, Pages 2039–2057]
[This corrects the article DOI: 10.1016/j.bioactmat.2020.12.025.].
- 1 October 2021
- Published by KEAI Publishing in Bioactive Materials
- Vol. 6 (10) , 3192-3193
Open AccessCorrigendum to ’Phosphorylation inhibition of protein-tyrosine phosphatase 1B tyrosine-152 induces bone regeneration coupled with angiogenesis for bone tissue engineering’ [Bioactive Mater. Vol. 6, Issue 7, Pages 2039–2057]
[This corrects the article DOI: 10.1016/j.bioactmat.2020.12.025.].
- 23 February 2017
- Published by Springer Nature in The AAPS Journal
- Vol. 19 (3) , 814-826
Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells
Lung cancer is the leading cancer and has the highest death rate. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has had a promising response in lung cancer...
- 23 February 2017
- Published by Springer Nature in The AAPS Journal
- Vol. 19 (3) , 814-826
Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells
Lung cancer is the leading cancer and has the highest death rate. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has had a promising response in lung cancer...
- Open Access
- 1 August 2013
- Published by S. Karger AG in Ophthalmologica
- Vol. 230 (2) , 55-61
Current Choroidal Neovascularization Treatment
Purpose: This paper aims to describe the current situation of choroidal neovascularization (CNV) treatment. Procedures: MEDLINE (2001-2013) was searched for original research studies (phase I, II, III), abstracts and review articles concerning CNV therapy, and other related articles. Selected information from related websites was also included. Results: The management of CNV was developed through laser photocoagulation and photodynamic therapy, and has now evolved into anti-vascular endothelial growth factor (VEGF) use. Patients have achieved better visual acuity and toleration with the development of this therapy strategy. Combination therapy appears to offer a reduced retreatment frequency and long-term maintenance of the benefit with appropriate combination. Other treatment explorations with anti-inflammation and anti-VEGF are also ongoing. Conclusions: Anti-VEGF monotherapy has become the first treatment for CNV patients. The investigation of other therapy strategies may prolong the interval of treatment and provide alternatives to CNV treatment.
- 1 August 2013
- Published by S. Karger AG in Ophthalmologica
- Vol. 230 (2) , 55-61
Open AccessCurrent Choroidal Neovascularization Treatment
Purpose: This paper aims to describe the current situation of choroidal neovascularization (CNV) treatment. Procedures: MEDLINE (2001-2013) was searched for original research studies (phase I, II, III), abstracts and review articles concerning CNV therapy, and other related articles. Selected information from related websites was also included. Results: The management of CNV was developed through laser photocoagulation and photodynamic therapy, and has now evolved into anti-vascular endothelial growth factor (VEGF) use. Patients have achieved better visual acuity and toleration with the development of this therapy strategy. Combination therapy appears to offer a reduced retreatment frequency and long-term maintenance of the benefit with appropriate combination. Other treatment explorations with anti-inflammation and anti-VEGF are also ongoing. Conclusions: Anti-VEGF monotherapy has become the first treatment for CNV patients. The investigation of other therapy strategies may prolong the interval of treatment and provide alternatives to CNV treatment.